GW Pharmaceuticals PLC- (GWPH) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a research note published on Tuesday. They currently have $161.00 price objective on the biopharmaceutical company’s stock.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

GWPH has been the topic of several other reports. ValuEngine cut shares of GW Pharmaceuticals PLC- from a buy rating to a hold rating in a research report on Thursday, August 2nd. Cantor Fitzgerald set a $235.00 price target on shares of GW Pharmaceuticals PLC- and gave the stock a buy rating in a research report on Thursday, July 12th. Stifel Nicolaus started coverage on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, August 14th. They set a buy rating and a $181.00 price target on the stock. BidaskClub raised shares of GW Pharmaceuticals PLC- from a sell rating to a hold rating in a research report on Saturday, August 11th. Finally, Morgan Stanley set a $227.00 price target on shares of GW Pharmaceuticals PLC- and gave the stock a buy rating in a research report on Thursday, October 11th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $184.13.

GWPH traded down $10.67 during trading on Tuesday, hitting $137.42. The company had a trading volume of 13,950 shares, compared to its average volume of 532,287. The stock has a market capitalization of $4.30 billion, a P/E ratio of -19.79 and a beta of 2.25. GW Pharmaceuticals PLC- has a one year low of $105.12 and a one year high of $179.65. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($2.40) by $1.14. The business had revenue of $3.46 million for the quarter, compared to analysts’ expectations of $2.00 million. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. On average, equities research analysts predict that GW Pharmaceuticals PLC- will post -9.13 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC acquired a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $109,000. Envestnet Asset Management Inc. acquired a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $119,000. Cowen Prime Services LLC increased its stake in shares of GW Pharmaceuticals PLC- by 708.0% during the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 885 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $166,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of GW Pharmaceuticals PLC- by 497.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 999 shares during the last quarter. 70.02% of the stock is currently owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply